Illumina Inc (NASDAQ:ILMN)., a leading player in the genomic sequencing industry, finds itself at a critical juncture as it navigates a shifting competitive landscape and global economic challenges.

Fintel reports that on February 10, 2025, Barclays downgraded their outlook for Illumina (NasdaqGS:ILMN) from Equal-Weight to ...

The placement of Illumina in China's unreliable entity list could have disruptive implications. Read why I remain bullish on ...

Illumina is part of the Health Care sector, which has an average P/E ratio of 26.07 and an average P/B of 3.53 The company ...

Illumina, Inc. ILMN reported better-than-expected results for its fourth quarter on Thursday. The company posted quarterly ...

The company forecast annual revenue of $4.28 billion to $4.4 billion for 2025, the midpoint of which is below analysts' ...

signaling a strong conviction in the stock's future performance. The daily trade report also highlighted ARK's increased investment in Illumina Inc (NASDAQ:ILMN), with a total of 63,407 shares ...

Calm returned to Wall Street, and tech stocks led U.S. indexes higher. The S&P 500 rose 0.7% Tuesday, a day after swinging ...

This follows a pattern of consistent buying in recent days, signaling a strong conviction in the stock's future performance. The daily trade report also highlighted ARK's increased investment in ...

Illumina, Inc. (NASDAQ:ILMN – Get Free Report)’s share price gapped down prior to trading on Tuesday after Barclays lowered their price target on the stock from $145.00 to $130.00.The stock ...